A Prospective Population-based Longitudinal Observational Cohort Study of Late-onset Epilepsy, and Subsequent Stroke and Dementia.

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

There is not much known about why some people develop seizures in adulthood, but some researchers think that it might be a warning from the body to highlight something may be wrong with the brain. A small number of people with first seizure in adulthood go on to experience problems like stroke or dementia later in life. However, stroke and dementia are common diseases, so it is not know whether there is a real association between these conditions. When people develop their first seizure in adult life, this is sometimes called Late-Onset Epilepsy. The NeuroFrailty study, will observe 'brain health' over the years following the onset of a seizure, to provide more information about people with these kinds of seizures.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• diagnosis of LOE or first seizure after the age of 18.

• diagnosis confirmed or established at a tertiary neurology centre.

• sequential cases will be used; in the unlikely event that eligible cases outstrip capacity, an annual cap of the first 150 patients per year per cohort will be used.

• established diagnosis of migraine.

• with or without therapeutic medications with antiepileptic properties.

Locations
Other Locations
United Kingdom
Lancashire Teaching Hospitals NHS
RECRUITING
Preston
Contact Information
Primary
Jasmine Wall, MB BChir
jasmine.wall@lthtr.nhs.uk
via switchboard
Time Frame
Start Date: 2022-05-05
Estimated Completion Date: 2027-01-12
Participants
Target number of participants: 360
Treatments
Case (Late-onset epilepsy)
Observational study - no intervention. Participants with first seizure or new diagnosis of epilepsy, in adulthood.~Inclusion criteria for cases includes:~* diagnosis of LOE or first seizure after the age of 18.~* diagnosis confirmed or established at a tertiary neurology centre.~* sequential cases will be used; in the unlikely event that eligible cases outstrip capacity, an annual cap of the first 150 patients per year per cohort will be used.~Exclusion criteria for cases includes:~* another 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma, vascular or congenital abnormality of likely aetiological significance.~* people with migraine or headache syndrome can be included in case group - the presence or absence of a seizure syndrome is mutually exclusive between case and control groups, not the presence or absence of migraine.
Control (migraine)
Inclusion criteria for controls includes:~* established diagnosis of migraine.~* with or without therapeutic medications with antiepileptic properties.~Exclusion criteria for controls includes:~* diagnosis of epilepsy or confirmed seizure.~* 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma.~However, in both cases and controls, people with dementia, alcohol excess, recreational drug use or pre-existing small vessel disease will be included, as excluding these conditions would bias against the inclusion of the population who may benefit from this research and against the inclusion of patients with high risk of small vessel disease.
Related Therapeutic Areas
Sponsors
Leads: Lancashire Teaching Hospitals NHS Foundation Trust

This content was sourced from clinicaltrials.gov